Zai Lab’s DLL3-Targeting ADC Receives FDA Orphan Drug Designation for Neuroendocrine Carcinomas Zai Lab Limited has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation…
Rocket Pharmaceuticals Reports Positive Early Safety Update for RP-A501 Phase 2 Trial in Danon Disease Rocket Pharmaceuticals, Inc. has announced encouraging early safety results from the first three patients treated…
Polpharma Biologics Advances PB016 as FDA and EMA Accept Biosimilar Applications for Review Polpharma Biologics International AG has announced a significant regulatory milestone with the acceptance of both its Biologics…
Bayer Submits New Drug Application in China to Expand Finerenone Use for Adults with Non-Diabetic Chronic Kidney Disease Bayer has announced the submission of a New Drug Application (NDA) to…
Novo Nordisk Reports Topline Results from Phase 3 ZEUS Trial Evaluating Ziltivekimab for Cardiovascular Risk Reduction Novo Nordisk has announced topline findings from its pivotal Phase 3 ZEUS cardiovascular outcomes…
EU Approval Positions Datroway® as the Only TROP2-Targeted Therapy with Overall Survival Benefit in First-Line Metastatic TNBC The European Commission (EC) has approved Datroway® (datopotamab deruxtecan) as a monotherapy for…
Polpharma Biologics’ Vedolizumab Biosimilar PB016 Accepted for FDA and EMA Review, Advancing Access to Biologic Therapy for Inflammatory Bowel Disease Polpharma Biologics International AG has announced that its proposed vedolizumab…
PHC Corporation of North America Launches Cell-IQ® CO₂ Incubator Series with Advanced Humidity Control and Contamination Prevention PHC Corporation of North America (PHCNA), a leading provider of PHCbi laboratory equipment…
Contineum Therapeutics Reports Second Quarter 2026 Financial Results and Reaffirms Clinical Development Milestones Across Inflammatory and Fibrotic Disease Pipeline Contineum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing differentiated…
CareDx Reports Strong Second Quarter 2026 Results with 52% Revenue Growth and Raises Full-Year Financial Outlook CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company focused on transplant medicine,…
Meitheal Pharmaceuticals Secures FDA Approval for Garzulys™ Biosimilar Insulin to Expand Diabetes Care in the U.S. Meitheal Pharmaceuticals, Inc., a Chicago-based biopharmaceutical company focused on the development and commercialization of…
PVP Labs to Present Taphalgin® Research at 2026 Military Health System Research Symposium, Highlighting a Novel Battlefield Pain Management Approach PVP Labs, a clinical-stage biotechnology company focused on developing innovative…